These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 37088640)

  • 1. Metabolic disorders across the body mass index spectrum in a Colombian population with nonalcoholic fatty liver disease.
    Builes-Montaño CE; Pérez-Giraldo E; Castro-Sánchez S; Rojas-Henao NA; Santos-Sánchez OM; Restrepo-Gutiérrez JC
    Rev Gastroenterol Mex (Engl Ed); 2024; 89(1):64-69. PubMed ID: 37088640
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical Characteristics and Metabolic Profiles of Non-Alcoholic Fatty Liver Disease (NAFLD) in Lean Patients and Their Comparison with Obese and Overweight NAFLD.
    Chakrabarty M; Jha AN; Sharma DJ
    J Assoc Physicians India; 2022 Apr; 70(4):11-12. PubMed ID: 35443531
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Liver and Cardiovascular Damage in Patients With Lean Nonalcoholic Fatty Liver Disease, and Association With Visceral Obesity.
    Fracanzani AL; Petta S; Lombardi R; Pisano G; Russello M; Consonni D; Di Marco V; Cammà C; Mensi L; Dongiovanni P; Valenti L; Craxì A; Fargion S
    Clin Gastroenterol Hepatol; 2017 Oct; 15(10):1604-1611.e1. PubMed ID: 28554682
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Prevalence and clinical features of non-alcoholic steatohepatitis in a hypertensive population].
    García-Carretero R; Barquero-Pérez O; Mora-Jiménez I; Soguero-Ruiz C; Goya-Esteban R; Rodríguez-Castro C; Ramos-López J
    Hipertens Riesgo Vasc; 2019; 36(3):130-136. PubMed ID: 30655210
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The impact of body mass index on clinicopathological features of nonalcoholic fatty liver disease in Taiwan.
    Lin CL; Tai CM; Huang JF; Liu CJ; Chen HF; Cheng PN; Chen CY; Peng CY; Wang CC; Weng SH; Tseng TC; Kao JH
    J Gastroenterol Hepatol; 2022 Oct; 37(10):1901-1910. PubMed ID: 35790343
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical and Patient-Reported Outcomes From Patients With Nonalcoholic Fatty Liver Disease Across the World: Data From the Global Non-Alcoholic Steatohepatitis (NASH)/ Non-Alcoholic Fatty Liver Disease (NAFLD) Registry.
    Younossi ZM; Yilmaz Y; Yu ML; Wai-Sun Wong V; Fernandez MC; Isakov VA; Duseja AK; Mendez-Sanchez N; Eguchi Y; Bugianesi E; Burra P; George J; Fan JG; Papatheodoridis GV; Chan WK; Alswat K; Saeed HS; Singal AK; Romero-Gomez M; Gordon SC; Roberts SK; El Kassas M; Kugelmas M; Ong JP; Alqahtani S; Ziayee M; Lam B; Younossi I; Racila A; Henry L; Stepanova M;
    Clin Gastroenterol Hepatol; 2022 Oct; 20(10):2296-2306.e6. PubMed ID: 34768009
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association between the lean nonalcoholic fatty liver disease and risk of incident type 2 diabetes in a healthy population of Northwest China: a retrospective cohort study with a 2-year follow-up period.
    Li N; Xang W; Wu S; Li D; Chang M; Xie C; Zhang MY; Tan H
    Front Endocrinol (Lausanne); 2023; 14():1173757. PubMed ID: 37435491
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nonalcoholic Fatty Liver Disease in Lean Subjects: Associations With Metabolic Dysregulation and Cardiovascular Risk-A Single-Center Cross-Sectional Study.
    Semmler G; Wernly S; Bachmayer S; Wernly B; Schwenoha L; Huber-Schönauer U; Stickel F; Niederseer D; Aigner E; Datz C
    Clin Transl Gastroenterol; 2021 Apr; 12(4):e00326. PubMed ID: 33821832
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lean-non-alcoholic fatty liver disease increases risk for metabolic disorders in a normal weight Chinese population.
    Feng RN; Du SS; Wang C; Li YC; Liu LY; Guo FC; Sun CH
    World J Gastroenterol; 2014 Dec; 20(47):17932-40. PubMed ID: 25548491
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevalence of nonalcoholic fatty liver disease and its metabolic risk factors in women of different ages and body mass index.
    Wang Z; Xu M; Hu Z; Shrestha UK
    Menopause; 2015 Jun; 22(6):667-73. PubMed ID: 25513983
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Global epidemiology of lean non-alcoholic fatty liver disease: A systematic review and meta-analysis.
    Lu FB; Zheng KI; Rios RS; Targher G; Byrne CD; Zheng MH
    J Gastroenterol Hepatol; 2020 Dec; 35(12):2041-2050. PubMed ID: 32573017
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevalence and risk factors of nonalcoholic fatty liver disease in an adult population of taiwan: metabolic significance of nonalcoholic fatty liver disease in nonobese adults.
    Chen CH; Huang MH; Yang JC; Nien CK; Yang CC; Yeh YH; Yueh SK
    J Clin Gastroenterol; 2006 Sep; 40(8):745-52. PubMed ID: 16940890
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nonalcoholic Fatty Liver Disease and Associated Risk Factors in Obese Nigerians: A Cross-Sectional Study.
    Onyia CP; Asogwa P; Adiri W; Obienu O; Ijoma UN; Nwokediuko SC; Okeke EN
    Niger J Clin Pract; 2024 Mar; 27(3):352-360. PubMed ID: 38528356
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical, anthropometric, biochemical, and histological characteristics of nonobese nonalcoholic fatty liver disease patients of Bangladesh.
    Alam S; Gupta UD; Alam M; Kabir J; Chowdhury ZR; Alam AK
    Indian J Gastroenterol; 2014 Sep; 33(5):452-7. PubMed ID: 25023045
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nonalcoholic fatty liver disease in lean subjects: Prognosis, outcomes and management.
    Chrysavgis L; Ztriva E; Protopapas A; Tziomalos K; Cholongitas E
    World J Gastroenterol; 2020 Nov; 26(42):6514-6528. PubMed ID: 33268944
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Growing burden of nonalcoholic fatty liver disease in Turkey: A single-center experience.
    Yılmaz Y; Kanı HT; Demirtaş CÖ; Kaya E; Sapmaz AF; Qutranji L; Alkayyali T; Batun KD; Batman M; Toy B; Çiftaslan A
    Turk J Gastroenterol; 2019 Oct; 30(10):892-898. PubMed ID: 31258138
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevalence of Nonalcoholic Steatohepatitis-Associated Cirrhosis in the United States: An Analysis of National Health and Nutrition Examination Survey Data.
    Kabbany MN; Conjeevaram Selvakumar PK; Watt K; Lopez R; Akras Z; Zein N; Carey W; Alkhouri N
    Am J Gastroenterol; 2017 Apr; 112(4):581-587. PubMed ID: 28195177
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Natural History of Nonalcoholic Fatty Liver Disease With Normal Body Mass Index: A Population-Based Study.
    Ahmed OT; Gidener T; Mara KC; Larson JJ; Therneau TM; Allen AM
    Clin Gastroenterol Hepatol; 2022 Jun; 20(6):1374-1381.e6. PubMed ID: 34265444
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Irisin in patients with nonalcoholic fatty liver disease.
    Polyzos SA; Kountouras J; Anastasilakis AD; Geladari EV; Mantzoros CS
    Metabolism; 2014 Feb; 63(2):207-17. PubMed ID: 24140091
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Global prevalence, incidence, and outcomes of non-obese or lean non-alcoholic fatty liver disease: a systematic review and meta-analysis.
    Ye Q; Zou B; Yeo YH; Li J; Huang DQ; Wu Y; Yang H; Liu C; Kam LY; Tan XXE; Chien N; Trinh S; Henry L; Stave CD; Hosaka T; Cheung RC; Nguyen MH
    Lancet Gastroenterol Hepatol; 2020 Aug; 5(8):739-752. PubMed ID: 32413340
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.